Meet us at these events

•  Global Health Exhibition, October 9-11, Riyadh

• ESICM, October 25-26, Paris

 •  Icare Congress, October 28-30, Milano

SAFE

No contraindications
Medical device class IIa (EU MDD)

SPECIFIC

Designed to specifically
remove endotoxin


EFFECTIVE

Results in 2 hours
1 treatment = 1 adsorber 

Endotoxin removal

Inside the Alteco LPS Adsorber, a tailor-made synthetic peptide binds to Lipid A; the toxic part of endotoxin. By adsorbing harmful levels of endotoxin from the patient’s bloodstream during extracorporeal treatment in the ICU, the Alteco LPS Adsorber breaks the chain of immune system over-reactions that can spiral into septic shock. This can turn the course of sepsis and stabilize the patient’s hemodynamic parameters in 2 hours. 2

Take endotoxin out of the picture

View our product animation to learn more about endotoxin removal and the Alteco LPS Adsorber.

Early treatment start

High levels of endotoxin activity are associated with organ failure and death. 3 Therefore, starting treatment early is important. Use the Alteco LPS Adsorber to counteract the critical and life-threatening part of the sepsis process. Remove endotoxin from the bloodstream to regain control over the systemic failure and stabilize the patient in the acute situation.

Treatment results and clinical benefits

Post treatment, patients usually demonstrate a reduction in endotoxin, procalcitonin and lactate levels, a reduction or elimination of vasopressor support, stability and improvement in hemodynamic parameters as well as SOFA score.

Applications

Manage sepsis in the ICU

Learn more about Alteco LPS Adsorber for treating sepsis and septic shock.

Preventive endotoxin removal in cardiac surgery

Endotoxin from gram-negative bacteria is a potent trigger of the inflammatory response, and endotoxemia is known to occur in cardiac surgery using extracorporeal circulation.

Sepsis in COVID-19 ICU patients

Learn more about Alteco LPS Adsorber for treating sepsis and septic shock in COVID-19 ICU patients, and the rationale for removing endotoxin.

Removing the threat

Our mission is to safely stabilize patients through extracorporeal endotoxin elimination, turning the course of sepsis before septic shock occurs.

Get the latest updates

    News

    Alteco Medical AB has entered into a distribution agreement with BTC Health, who is now appointed exclusive distributor for Alteco LPS Adsorber in Australia and New Zealand.
    Alteco Medical has signed a distribution agreement with Incardia Biomedical Spa in Chile.
    Alteco Medical has signed distribution contracts with new distributors in Panama and Iraq.
    Alteco Medical has signed a contract with Medvision in Kuwait.
    Alteco Medical welcomes distributors in Taiwan and Switzerland: Brojaw Inc. and Somapharm AG.
    Alteco Medical has added distributors on two large markets: France and South Korea.